Evaluation of the efficacy and tolerability of zoledronic acid in combination with radiotherapy in patients with advanced osteolytic bone lesions

Trial Profile

Evaluation of the efficacy and tolerability of zoledronic acid in combination with radiotherapy in patients with advanced osteolytic bone lesions

Completed
Phase of Trial: Phase IV

Latest Information Update: 25 Apr 2017

At a glance

  • Drugs Zoledronic acid (Primary)
  • Indications Cancer; Cancer metastases; Pain
  • Focus Therapeutic Use
  • Sponsors Novartis
  • Most Recent Events

    • 25 Apr 2012 Actual end date (December 2008) added as reported by ClinicalTrials.gov.
    • 25 Apr 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 06 Oct 2009 Planned number of patients changed from 100 to 75 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top